Celgene (CELG +0.6%) says it's been notified by the FDA that there won't be an Oncologic Drugs Advisory Committee meeting scheduled for November 8. Its review of the company's NDA for pomalidomide will continue with the previously announced PDUFA action date of Feb. 10, 2013. Pomalidomide is a potential blockbuster for CELG, and the company has been hoping for an early approval of of the drug to be used in combination with dexamethasone as a treatment for patients with myeloma.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Tue, 6:33PM)
at Investor's Business Daily (Fri, 6:51PM)
Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blogat Zacks.com (Feb 26, 2015)
at Nasdaq.com (Feb 24, 2015)
at Zacks.com (Feb 23, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs